Company
Company
Arrows show the direction of the relationship. Filter to focus on a business area.
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.View source
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.View source
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.View source
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.View source
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.View source
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.View source
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.View source
Showing 1 to 7 of 7
Read the assertion alongside its sources. Expand a row to inspect the evidence.
Innovent has launched 20 products in the market.
PR Newswire news releases · 2026-10-09
Innovent has launched 20 products in the market.View source
It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.
PR Newswire news releases · 2026-10-09
It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.View source
It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.
PR Newswire news releases · 2026-10-09
It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.View source
It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.
PR Newswire news releases · 2026-10-09
It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 more molecules in early clinical stage.View source
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
PR Newswire news releases · 2026-10-09
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.View source
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
PR Newswire news releases · 2026-10-09
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.View source
Showing 1 to 6 of 11
Valuation data is available on Pro and Research.
Included in ProNot available: Company signals · Financials · Filings · Guidance
